<DOC>
	<DOCNO>NCT00948935</DOCNO>
	<brief_summary>This study evaluate combination chemotherapy gemcitabine , irinotecan panitumumab patient advance biliary cancer .</brief_summary>
	<brief_title>Study Gemcitabine , Irinotecan Panitumumab Patients With Advanced Metastatic Biliary Tract Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>histologically cytologically confirm local advance unresectable/metastatic adenocarcinoma biliary tract measurable disease available tumor tissue investigational immunohistochemical evaluation ECOG PS 02 No prior chemotherapy , biologic therapy radiation therapy Age Eighteen old Lab value per protocol Life expectancy less three month Concurrent use chemotherapy indicate study protocol investigational agent patient receive investigational drug less four week prior enrollment Prior therapy , affect target EGF pathway Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer Recovery major surgery within three week start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Biliary Cancer</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Panitumumab</keyword>
</DOC>